이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

당뇨병 진단 후 췌장 건강의 감시 (SAFE-D)

An Interventional Study to Evaluate the cfDNA Pancreatic Cancer Test (Avantect) in the Early Detection of Pancreatic Cancer in Participants With Newly Diagnosed Diabetes Mellitus or Newly Elevated HbA1c

The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days.

Participants will:

  • attend 3 study visits over 12 months time
  • provide a blood sample at each study visit
  • complete an anxiety questionnaire at each visit.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Pancreatic cancer (PC) is one of the most lethal common cancers (five-year survival 5-7%). In more than 80% of patients the disease has spread before it is detected, ruling out potentially curative treatment options. Early detection offers the possibility of surgery leading to significantly improved overall survival.

There is currently no accepted screening test for pancreatic cancer. The Aventect test is designed to detect clues, or biomarkers for the presence or absence of pancreatic cancer signals in blood. The SAFE-D study will evaluate if the Avantect test can detect pancreatic cancer at an earlier more treatable stage.

People older than 50 years who have recently been diagnosed with type II diabetes have up to ten times higher-than-average risk of having pancreatic cancer without knowing.

The study will recruit 5,000 participants aged 50-84 years old diagnosed with type II diabetes or elevated Hb1Ac levels within the last 200 days from GP practices over 3 years.

Participants will have their blood samples analysed on the Avantect test as soon as possible. If a pancreatic biomarker is detected the participants will be informed and offered a standard of care diagnostic imaging scan (MRI or CT) to rule out pancreatic cancer. All participants will be followed remotely via cancer and mortality registry searches for 3 years from consent to assess any cancer diagnosed during this time.

연구 유형

중재적

등록 (추정된)

5000

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: SAFE-D Trial Manager
  • 전화번호: +442381205154
  • 이메일: safed@soton.ac.uk

연구 장소

      • Ashton-under-Lyne, 영국, OL6 6HD
        • 모집하지 않고 적극적으로
        • Ashton Medical Group
      • Birmingham, 영국, B14 4DU
        • 모병
        • Yardley Wood Health Centre
        • 연락하다:
      • Bournemouth, 영국, BH7 7DW
        • 모집하지 않고 적극적으로
        • Bournemouth Research Hub
      • Bromborough, 영국, CH62 6EE
        • 모병
        • Eastham Group Practice
        • 연락하다:
      • London, 영국, NW10 2PT
        • 모병
        • Willesden Medical Centre
        • 연락하다:
      • London, 영국, SW1P 2PF
        • 모병
        • South Westminster Centre
        • 연락하다:
      • London, 영국, W7 1DR
        • 모병
        • The Cuckoo Lane Practice
        • 연락하다:
      • Manchester, 영국, M14 6WP
        • 모집하지 않고 적극적으로
        • Bodey Medical Centre
      • Manchester, 영국, M23 1JX
        • 모집하지 않고 적극적으로
        • Bowland Medical Practice
      • Manchester, 영국, M23 2SY
        • 모집하지 않고 적극적으로
        • The Maples Medical Centre
      • Nottingham, 영국, NG17 4JL
        • 모병
        • King's Mill Hospital (Sherwood Forest) Research Van
        • 연락하다:
      • Portsmouth, 영국, PO1 3HN
        • 모집하지 않고 적극적으로
        • Portsmouth Research Hub
      • Rossendale, 영국, BB4 5SL
        • 모병
        • Hazelvalley Family Practice
        • 연락하다:
      • Ruislip, 영국, HA4 8NX
        • 모병
        • Pembroke Centre (Hillingdon)
        • 연락하다:
      • Southampton, 영국, SO30 3JB
        • 모병
        • Moorgreen Hospital
        • 연락하다:
      • Southampton, 영국, SO15 33UA
        • 모집하지 않고 적극적으로
        • Southampton Research Hub (Shirley Research Hub)
      • Uttoxeter, 영국, ST14 8JG
        • 모병
        • Balance Street Health Centre
        • 연락하다:
      • Uxbridge, 영국, UB8 1UW
        • 모병
        • Civic Centre
        • 연락하다:
      • Walsall, 영국, WS6 6EW
        • 모병
        • Quinton Practice
        • 연락하다:
      • Weymouth, 영국, DT4 0QE
        • 모집하지 않고 적극적으로
        • Weymouth Research Hub
    • Cheshire
      • Sandbach, Cheshire, 영국, CW11 1EQ
        • 모집하지 않고 적극적으로
        • Ashfields Primary Care Centre
    • Kent
      • Maidstone, Kent, 영국, ME16 9QQ
        • 모병
        • Maidstone and Tunbridge Wells NHS Trust
        • 연락하다:
    • Leicester Forest East
      • Leicester, Leicester Forest East, 영국, LE3 3LW
        • 모병
        • Forest Medical Group
        • 연락하다:
    • Leicestershire
      • Kibworth Beauchamp, Leicestershire, 영국, LE8 0LG
        • 모병
        • South Leicestershire Medical Group
        • 연락하다:
    • Staffordshire
      • Burton-on-Trent, Staffordshire, 영국, DE14 3RH
        • 모병
        • Peel Croft Surgery
        • 연락하다:
      • Kingswinford, Staffordshire, 영국, DY6 8DN
        • 모병
        • Kingswinford Medical Practice
        • 연락하다:
      • Leek, Staffordshire, 영국, ST13 6QR
        • 모병
        • Park Medical Centre
        • 연락하다:
      • Stratford-upon-Avon, Staffordshire, 영국, CV37 6HJ
        • 모병
        • Trinity Court Surgery
        • 연락하다:
    • Surrey
      • Brockham, Surrey, 영국, RH3 7NJ
        • 모병
        • Brockwood Medical Practice
        • 연락하다:
      • Epsom, Surrey, 영국, KT17 4BL
        • 모병
        • Integrated Care Partnership/ The Old Cottage Hospital
        • 연락하다:
      • Warlingham, Surrey, 영국, CR6 9NW
        • 모병
        • Warlingham Green Medical Practice
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

50년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • 50 - 84 years of age at the time of enrolment (within year of birth, not month of birth)
  • Confirmed type 2 DM diagnosis established within the last 200 days or an initial elevated HbA1c ≥ 48 mmol/mol or 6.5% obtained within the last 200 days. This includes people who have a first elevated HbA1c (≥ 48 mmol/mol or 6.5%) within the last 200 days, even if subsequent HbAc1 measurements return to the the normal range.
  • Willing to provide up to 30 mL of blood for each study visit
  • Willing and eligible to undergo MRI or CT scan
  • Understands the study process and is willing to take part in the study and sign the informed consent form

Exclusion Criteria:

  • Prior type I or type II DM diagnosis or an initial HbA1c ≥ 48 mmol/mol or 6.5% obtained prior to the 200-day inclusion window, except gestational elevated HbA1c.
  • A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis
  • Under investigation for or confirmed pancreatic cancer
  • Under investigation/surveillance for pancreatic cyst
  • Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months
  • Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years
  • BMI > 40 at the time of consent
  • Blood transfusion within 1 month
  • Solid organ transplant recipient
  • Currently pregnant
  • Needing dialysis

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 특수 증상
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Interventional

Participants will have their blood samples tested on the Avantect test within prioritised timeframe. The "detected" Avantect test results will be shared with the participants and their General Practitioners (GPs) to allow for further MRI or CT investigations by the local clinical team.

Avantect test

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Sensitivity of the Avantect test
기간: The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.

The proportion of individuals with one or more Avantect "detected" test result who have pancreatic cancer diagnosed via imaging in relation to all individuals in the study who had pancreatic cancer diagnosed.

The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
Specificity of the Avantect test
기간: The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

The proportion of individuals with one or more Avantect "not detected" test results, and no Avantect "detected" results, who did not have a pancreatic cancer diagnosis in relation to all individuals in the study who did not have a pancreatic cancer diagnosis.

The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

2차 결과 측정

결과 측정
측정값 설명
기간
Stage shift
기간: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

The proportion of pancreatic cancers cases diagnosed at stage I/II out of all participants diagnosed with pancreatic cancer between SAFE-D participants and point-estimate of the proportion from comparative data.

Stage shift will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data.

The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
Positive Predictive Value (PPV) of Avantect test in detecting pancreatic cancer (PC)
기간: The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

Percentage of participants with an Avantect "detected" result who have pancreatic cancer diagnosed. The analysis will be conducted with a sample size of 5,000, pancreatic cancer prevalence of 0.8%, and 5% lost from the per protocol population. There will be an expected 261 individuals with an Avantect "detected" result. 9.6% (25/261) are expected to have a PC. PPV will be considered successful if a null PPV of 5% can be ruled out at a one-sided p-value of 0.05.

The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
Negative Predictive Value (NPV) of Avantect test in ruling out pancreatic cancer (PC)
기간: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

With a sample size of 5,000, PC prevalence of 0.8%, and 5% lost from the per protocol population, there will be an expected 4,489 individuals without an Avantect "detected" result. 99.6% (4,476/4,489) are expected to not have a diagnosis of PC. NPV will be considered successful if a null NPV of 99% can be ruled out at a one-sided p-value of 0.05.

The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
Resection rate of pancreatic cancer
기간: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

Percentage of participants with pancreatic cancer who underwent resection. The analysis will be conducted by comparing the proportion of pancreati cancer cases that underwent resection as a treatment modality between SAFE-D participants and the point-estimate of the proportion from comparative data. Resection rate will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data.

The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
Resectability
기간: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

Percentage of pancreatic cancers deemed resectable by the study MDST.

The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

기타 결과 측정

결과 측정
측정값 설명
기간
Time-to-event outcomes
기간: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

To estimate the time from new onset diabetes diagnosis to pancreatic cancer diagnosis.

The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
Overall survival
기간: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

To estimate the overall survival of study participants.

The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
Effect of the Avantect test on state anxiety over time
기간: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

To assess the effect of the Avantect test on state anxiety over time.

The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
High-grade neoplasia
기간: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

To investigate the performance characteristics for high-grade neoplasia.

The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 5월 21일

기본 완료 (추정된)

2029년 7월 29일

연구 완료 (추정된)

2032년 7월 1일

연구 등록 날짜

최초 제출

2025년 1월 27일

QC 기준을 충족하는 최초 제출

2025년 1월 27일

처음 게시됨 (실제)

2025년 1월 31일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 28일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 25일

마지막으로 확인됨

2026년 3월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • RHMGSU0292

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .